IP Library Granted Patent US 7,179,613
Granted Patent B2
US 7,179,613 · App. 10/838,167 · Granted Feb 20, 2007

Methods of screening for a candidate modulator of glucokinase

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,179,613
App. No.
10/838,167
Granted
Feb 20, 2007
Kind
B2
Abstract

The present invention relates to providing novel therapeutics for treating diabetes other glycemic disorders. Such therapeutics involve the signaling pathways that contribute to regulation of glucose-stimulated insulin secretion. Of particular interest are modulators of a key component in the glucokinase pathway. Thus, the present provides methods of screening for modulators of glucokinase activity, expression, translocation, conformation, nitrosylation and interaction with other molecules as useful target for pharmacological manipulation in the treatment of diabetes and other glycemic disorders.

Claims (16)

1. A method of screening a candidate substance for modulation of glucokinase (GK) comprising:

(a) providing an insulin-responsive cell expressing a GK molecule;

(b) contacting said cell with said candidate substance; and

(c) measuring translocation of said GK molecule into the cytoplasm of said cell,

wherein a change in the translocation of said GK molecule into the cytoplasm of said cell, as compared to that seen in a similar cell not treated with said candidate substance, indicates that said candidate substance is a modulator of said GK molecule.

2. The method of claim 1 , wherein said insulin-responsive cell is an immortalized pancreatic cell.

3. The method of claim 1 , wherein said insulin-responsive cell is an insulinoma cell.

4. The method of claim 1 , wherein said insulin-responsive cell is treated with insulin, NO or high glucose concentrations.

5. The method of claim 1 , wherein said insulin-responsive cell is subjected to low glucose concentrations.

6. The method of claim 1 , wherein measuring comprises fluorescence photobleaching.

7. The method of claim 6 , wherein said GK molecule is labeled with yellow fluorescent protein, and secretory granules are labeled with cyan fluorescent protein.

8. The method of claim 4 , further comprising performing a control reaction using an inhibitor of nitric oxide synthase.

9. The method of claim 1 , wherein said candidate substance is a peptide or protein.

10. The method of claim 1 , wherein said candidate substance is a nucleic acid.

11. The method of claim 1 , wherein said candidate substance is an activator of said GK molecule.

12. The method of claim 1 , wherein said candidate substance is an inhibitor of said GK molecule.

Assignments (3)
SECURITY INTEREST Recorded Jan 5, 2023
From: LUMILEDS LLC; LUMILEDS HOLDING B.V.
To: SOUND POINT AGENCY LLC
Reel/Frame 062299/0338 →
CONFIRMATORY LICENSE Recorded Aug 5, 2008
From: VANDERBILT UNIVERSITY
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 021337/0806 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 21, 2004
From: RIZZO, MARK A.; PISTON, DAVID W.
To: VANDERBILT UNIVERSITY
Reel/Frame 015800/0673 →